These findings suggest that inhibiting the degradation of PP using specific inhibitors and/or the design of analogs resistant to cleavage by DPPIV and NEP might be useful in the development of PP as an anti-obesity pharmacotherapy. Here, DPP4 is linked to obesity due to melanocortin 4 receptor deficiency.